Table 1 Clinical characteristics of the study population.
From: Ocular surface manifestation of COVID-19 and tear film analysis
Age, years | 77.1 ± 12.6 |
Male, n (%) | 15 (51.7%) |
Disease severity | |
Severe, n (%) | 7 (24.1%) |
Moderate, n (%) | 22 (75.9%) |
Duration of COVID-19, days | 18.7 ± 7.9 |
0 − 10 days | 5 (17.2%) |
10 − 20 days | 11 (38%) |
> 20 days | 13 (44.8%) |
Temperature, °C | 37.3 ± 0.8 |
Comorbidities | |
Hypertension, n (%) | 25 (86.2%) |
Diabetes, n (%) | 18 (62.1%) |
Obesity, n (%) | 13 (44.8%) |
Coronary heart disease, n (%) | 8 (27.5%) |
Cerebrovascular disease, n (%) | 7 (24.1%) |
Atrial fibrillation, n (%) | 7 (24.1%) |
Neurological disease, n (%) | 4 (13.8%) |
Cancer, n (%) | 9 (31%) |
BPCO, n (%) | 9 (31%) |
Smoker, n (%) | 5 (17.2%) |
Chronic renal disease, n (%) | 7 (24.1%) |
Therapy | |
Antibiotics, n (%) | 26 (89.6%) |
Antiviral, n (%) | 9 (31%) |
Corticosteroids, n (%) | 13 (44.8%) |
Low molecular weight heparin, n (%) | 26 (89.6%) |
Hydroxychloroquine, n (%) | 19 (65.5%) |
